1.06 is Pfizer Inc’s (NYSE:PFE) Big Money Sentiment

May 16, 2018 - By Nicole Mills

Pfizer Inc. (NYSE:PFE) Corporate Logo

Positions for Pfizer Inc (NYSE:PFE)

In 2017 Q4 Pfizer Inc (NYSE:PFE) big money sentiment increased to 1.06, SEC filings reveal. That’s up 0.10, from 2017Q3’s 0.96. 766 institutional investors started new or increased holdings, while 726 reduced and sold their stock positions in Pfizer Inc so the sentiment is positive. Funds own 4.07 billion shares, up from 4.06 billion shares in 2017Q3. Funds holding Pfizer Inc in top 10 changed to 112 from 139 for a decrease of 27. In total 51 funds closed positions, 675 reduced and 632 increased. Also 134 funds bought new Pfizer Inc stakes.

Biggest Pfizer Inc Investors

As of 2017 Q4 Northeast Financial Consultants Inc has 16.02% invested in Pfizer Inc. Pfizer Inc’s shareholder Knott David M owns 933,276 shares as of 2017 Q4. New England Professional Planning Group Inc. reported 233,894 shares. The New York-based fund Stuyvesant Capital Management have invested about 9.06% of the investment manager’s stock portfolio in Pfizer Inc. The Arkansas-based fund Foundation Resource Management Inc looks positive on Pfizer Inc, possessing 1.26 million shares.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide.The firm is worth $209.21 billion. It operates through two divisions, Pfizer Innovative Health and Pfizer Essential Health (EH).The P/E ratio is 9.94. The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Ticker’s shares touched $35.765 during the last trading session after 0.21% change.Currently Pfizer Inc. is uptrending after 2.43% change in last May 16, 2017. PFE has 6.89 million shares volume. PFE underperformed by 9.12% the S&P500.

Earnings report for Pfizer Inc. (NYSE:PFE) is anticipated on August, 7., Faxor reports. Analysts forecast $0.75 EPS, which is $0.08 up or 11.94 % from 2017’s $0.67 EPS. PFE’s profit could hit $4.39 billion with 11.92 P/E in case $0.75 EPS is revealed. Wall Street now predicts -2.60 % negative EPS growth despite Pfizer Inc. previous quarter’s EPS of $0.77.

98,590 were reported by Bancshares Hapoalim Bm. Leavell Inv Management Inc, a Alabama-based fund reported 131,032 shs. The Texas-based Cadence Bank & Trust Na has invested 1.35% in Pfizer Inc. (NYSE:PFE). Washington-based Coldstream Capital Management has invested 0.36% in Pfizer Inc. (NYSE:PFE). 21,908 were reported by Partnervest Advisory Ser Limited Liability. Asset One Com Limited owns 9.62M shs or 0.77% of their US capital. 76,370 were reported by Lodestar Invest Counsel Limited Co Il. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Invest Corporation holds 0.03% or 99,300 shs. Fred Alger Management Inc owns 98,348 shs. Dekabank Deutsche Girozentrale holds 1.25% in Pfizer Inc. (NYSE:PFE) or 4.82M shs. Kcm Invest Ltd Limited Liability Company holds 0.56% in Pfizer Inc. (NYSE:PFE) or 262,335 shs. Rock Point Advsrs Ltd Liability Corporation owns 20,836 shs or 0.35% of their US capital. Louisiana State Employees Retirement Sys accumulated 360,900 shs. Ipswich Investment Communication Inc reported 0.51% in Pfizer Inc. (NYSE:PFE). James Investment Rech Inc invested in 0.93% or 754,756 shs.

Pfizer Inc. registered $17.75 million net activity with 0 insider buys and 13 selling transactions since December 15, 2017. 9,510 shs were sold by LUND-JURGENSEN KIRSTEN, worth $353,677 on Saturday, February 24. On Friday, March 2 a trade for 13,986 shs valued at $501,398 was made by Dolsten Mikael. MACKENZIE ALEXANDER R sold $249,750 worth of stock. On Tuesday, March 13 LANKLER DOUGLAS M sold $1.84M worth of Pfizer Inc. (NYSE:PFE). The insider READ IAN C sold 132,312 shs worth $4.76M. On Monday, February 26 a trade for 33,368 shs valued at $1.24M was made by SUSMAN SALLY.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

A total of 9 analysts rate Pfizer (NYSE:PFE) as follows: 3 “Buy”, 5 “Hold” and 1 “Sell”. Тherefore 33% are bullish. (NYSE:PFE) has 14 ratings reports on 16 May 2018 according to StockzIntelligence. On Sunday, January 28 SunTrust maintained Pfizer Inc. (NYSE:PFE) with “Hold” rating. The stock rating was downgraded by Barclays Capital to “Equal-Weight” on Thursday, April 5. On Wednesday, January 31 the stock of Pfizer Inc. (NYSE:PFE) has “Overweight” rating given by Morgan Stanley. In Monday, February 26 report Jefferies maintained it with “Hold” rating and $39.0 target. The company rating was maintained by Jefferies on Friday, April 13. In Tuesday, January 16 report Jefferies maintained it with “Hold” rating and $40.0 target. The stock rating was maintained by Credit Suisse with “Neutral” on Wednesday, January 31. On Wednesday, January 31 the rating was maintained by Leerink Swann with “Market Perform”. On Tuesday, November 21 BMO Capital Markets maintained Pfizer Inc. (NYSE:PFE) rating. BMO Capital Markets has “Buy” rating and $39.0 target. On Friday, December 15 the stock of Pfizer Inc. (NYSE:PFE) has “Buy” rating given by BMO Capital Markets.

For more Pfizer Inc. (NYSE:PFE) news announced briefly go to: Seekingalpha.com, Streetinsider.com, 247Wallst.com, Seekingalpha.com or Fool.com. The titles are as follows: “Pfizer Is A Definite Buy For 2018” announced on April 30, 2018, “Pfizer (PFE) Announces FDA Approval for Biosimilar RETACRIT” on May 15, 2018, “What to Look For in the Merck and Pfizer Reports Tuesday Morning” with a publish date: April 30, 2018, “Pfizer: Buy This Dip?” and the last “Better Buy: Pfizer Inc. (PFE) vs. Merck (MRK)” with publication date: May 13, 2018.

Pfizer Inc. (NYSE:PFE) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: